Pfizer (United States)-ko ikertzaileekin lankidetzan egindako argitalpenak (31)

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2021

  1. Management of particular clinical situations in psoriatic arthritis: an expert’s recommendation document based on systematic literature review and extended Delphi process

    Rheumatology International, Vol. 41, Núm. 9, pp. 1549-1565

2020

  1. Disease features associated with a low disease impact in patients with psoriatic arthritis: Results of a cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 22, Núm. 1

  2. The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review

    Rheumatology and Therapy, Vol. 7, Núm. 2, pp. 237-257

2019

  1. Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis

    Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715

2018

  1. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies

    Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 573-579

2017

  1. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

    Scientific Reports, Vol. 7

  2. Minimal disease activity and impact of disease in psoriatic arthritis: A Spanish cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 19, Núm. 1

2016

  1. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. Prevalence and clinical features of psoriatic arthritis in psoriasis patients in spain. Limitations of PASE as a screening tool

    European Journal of Dermatology, Vol. 25, Núm. 1, pp. 57-63

2014

  1. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 5, pp. 685-695

  2. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma

    Journal of Clinical Oncology, Vol. 32, Núm. 8, pp. 760-767

2013

  1. A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs

    Annals of Clinical Psychiatry, Vol. 25, Núm. 1, pp. 17-26

2012

  1. Pregabalin for the discontinuation of long-term benzodiazepines use: An assessment of its effectiveness in daily clinical practice

    European Psychiatry, Vol. 27, Núm. 4, pp. 301-307

  2. Quality of life in depressed women over 40 years old

    Actas Espanolas de Psiquiatria, Vol. 40, Núm. 4, pp. 221-227

2011

  1. Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: Is there still room for improvement?

    Annals of General Psychiatry, Vol. 10

  2. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use

    European Addiction Research, Vol. 17, Núm. 5, pp. 262-270

  3. High-dose etanercept in ankylosing spondylitis: Results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)

    Rheumatology, Vol. 50, Núm. 10, pp. 1828-1837

  4. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study

    European Neuropsychopharmacology, Vol. 21, Núm. 12, pp. 867-875

2010

  1. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort

    Schizophrenia Research, Vol. 119, Núm. 1-3, pp. 101-109